The shares of SynAct Pharma AB (publ) – with the ticker “SYNACT” – started trading on Nasdaq Stockholm’s main list on July 12, 2022.

“SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for SynAct, which enables us to accelerate the development of our lead candidate drug AP1189 through our clinical programs in RA, NS and other chronic diseases and subsequent commercialization. The move gives us access to more international and institutional investors, who will be key to our ambitious growth plans,” said Jeppe Øvlesen, CEO of SynAct Pharma.

SynAct’s share is traded in the Mid Cap segment and has retained both its ticker (SYNACT) and ISIN code (SE0008241491). In connection with the list change from Spotlight Stock Market, there was no offering or issue of new shares and shareholders of SynAct did not need to take any actions.

A listing of the Company’s shares on Nasdaq Stockholm is an important step in SynAct’s continued development and gives the Company further access to the Swedish and international capital markets. SynAct has been listed on Spotlight Stock Market since 2016, but the board of directors believes that the listing of the Company’s share on Nasdaq Stockholm will increase the conditions for broadening SynAct’s shareholder base and give the Company access to additional international and institutional investors, which is deemed to promote the Company’s continued development. Furthermore, the listing also carries a quality stamp for SynAct and its operations.